This is bad news - CEP 1347 was hoped to be an effective neuroprotective
agent. To make matters worse, the 200  PWP who volunteered for this trial
over the last two years, received no notification or explanation from the
trial sponsors - Cephalon and Lundbeck. Nor were their doctors advised.
Trial participants found out their trial was over through Internet news
sites. They deserved better treatment than that. They deserved an
explanation and medical advice on stopping the medication.
They deserved to be treated better than lab animals.
See the Parkinson's Pipeline Project's proposed "Research Participants
Bill of Rights"
http://pdpipeline.org/rights.htm

Linda Herman


FROM: PR Newswire US
May 11, 2005 Wednesday  08:50 PM GMT

HEADLINE: Cephalon and H. Lundbeck Announce Discontinuation of CEP-1347
Clinical
Trial in Parkinson's Disease

   FRAZER, Pa., May 11  /PRNewswire-FirstCall/ -- Cephalon, Inc.
(NASDAQ:CEPH)
and H. Lundbeck A/S (CSE:LUN) announced today the discontinuation of
their Phase
2/3 clinical trial of CEP-1347 in Parkinson's disease.  An independent
data
monitoring committee just completed a planned review of interim results
and
concluded that the data are unlikely to provide evidence of significant
effect.
There were no safety concerns.

   The study was being conducted by the Parkinson Study Group, a
non-profit,
cooperative group of Parkinson's disease experts from medical centers in
the
United States and Canada who are dedicated to improving treatment for
persons
affected by Parkinson's disease.

   "While we are disappointed with results of the trial, our
collaboration with
Lundbeck will continue as a valuable part of our ongoing research program
in
neurodegenerative disorders," said Dr. Jeffry L. Vaught, Senior Vice
President
and President, Research and Development at Cephalon.  "We will continue
to
actively evaluate compounds for further clinical development with
Lundbeck."

   Cephalon, Inc.

   Cephalon, Inc. is an international biopharmaceutical company dedicated
to the
discovery, development and marketing of innovative products to treat
sleep and
neurological disorders, cancer and pain.  The company currently markets
three
proprietary products in the United States: PROVIGIL (modafinil) Tablets
[C-IV],
GABITRIL(R) (tiagabine hydrochloride) Tablets and ACTIQ(R) (oral
transmucosal
fentanyl citrate) [C-II] and more than 20 products internationally.
Further
information about Cephalon and full prescribing information on its U.S.
products
is available at  http://www.cephalon.com/  or by calling 1-800-896-5855.

   H. Lundbeck A/S

   H. Lundbeck A/S is an international pharmaceutical company engaged in
the
research and development, production, marketing and sale of drugs for the
treatment of psychiatric and neurological disorders.  The company
currently
employs approximately 5,000 people, and in 2004 its revenue was DKK 9.7
billion.

   In addition to historical facts or statements of current condition,
this
press release may contain forward-looking statements.  Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events.  These may include statements regarding anticipated scientific
progress
on its research programs, development of potential pharmaceutical
products,
interpretation of clinical results, market prospects for its products,
sales and
earnings guidance, and other statements regarding matters that are not
historical facts.  You may identify some of these forward-looking
statements by
the use of words in the statements such as "anticipate," "estimate,"
"expect,"
"project," "intend," "plan," "believe" or other words and terms of
similar
meaning.  Cephalon's performance and financial results could differ
materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries as well as more specific
risks and
uncertainties facing Cephalon such as those set forth in its reports on
Form
8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect.  Therefore, you should not rely on
any
such factors or forward-looking statements. Furthermore, Cephalon does
not
intend to update publicly any forward-looking statement, except as
required by
law.  The Private Securities Litigation Reform Act of 1995 permits this
discussion.

   CONTACT:  Media: Robert W. Grupp, +1-610-738-6402,
[log in to unmask] ,
or Investors: Chip Merritt, +1-610-738-6376,  [log in to unmask] ,
both of
Cephalon; or Lundbeck Contacts: Steen Juul Jensen, Vice President,
+45 36 43 30 06, or Jacob Tolstrup, Investor Relations, +45 36 43 30 79,
or
Helle Hedegaard Juhl, Media Relations, +45 36 43 41 68

   Web site:   http://www.cephalon.com/

   Company News On-Call:   http://www.prnewswire.com/comp/134563.html

   SOURCE Cephalon, Inc.

URL: http://www.prnewswire.com

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn